Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer. Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, et al. Clin Cancer Res 2023 Jun 8:CCR-23-0375. doi: 10.1158/1078-0432.CCR-23-0375.

Read + Share

Amedeo Smart

Independent Medical Education

Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, et al. Targeting BCL2 overcomes resistance and augments response to aurora kinase B inhibition by AZD2811 in small cell lung cancer. Clin Cancer Res 2023 Jun 8:CCR-23-0375. doi: 10.1158/1078-0432.CCR-23-0375.
PMID: 37289191